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Developing a computer database for registering and monitoring 
patients on chronic drug therapy to determine drug 
consumption: a pilot study
CB TSOTO, GC MAPONGA, D GWATA
Abstract
Objectives: To develop a computerised database for monitoring actual drug consumption by a group of 
patients on chronic drug therapy and pilot the database to assess its effectiveness.
Setting: Community based in Chitungwiza, Zimbabwe.
Subjects: 434 patients with asthma, hypertension, epilepsy, Diabetes mellitus or multiple conditions whose 
medical information was entered into the database.
Main Outcome Measure: Accessibility of information on the exact amount of drugs being utilised by patients. 
Results: It was possible to determine the amount of drugs being consumed by the patients on chronic drug 
therapy from the database. Additional information on patient demographic data as well as adverse drug 
reactions could be compiled from that basic data. The database could also be used to follow up patients and 
record any changes in their treatment regimens and other relevant clinical information.
Conclusion: It is feasible to create a database for monitoring actual drug consumption by patients on chronic 
drug therapy as a way of forecasting drug requirements accurately. Such a database has more advantages over 
the current methods used to estimate drug requirements. It could also be very useful as an information resource 
centre for nation-wide use.
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Introduction
Zimbabwe has a National Drug Policy whose major goal is 
to ensure that all Zimbabweans have access to safe, effective 
and good quality medicines.1 Challenges to this goal not 
only include the disproportionately rising cost of drugs, 
but their shortage as well. This makes it difficult to achieve 
treatment goals for patients with chronic medical conditions
as they subsequently fail to pay for the drugs, resulting in 
poor management of their conditions. The situation is 
further compounded by continuous local currency 
devaluation, coupled with the country’s over-dependence 
on imported raw materials and finished drug products. 
Consequently people with chronic conditions such as 
asthma, cancer, Diabetes mellitus, hypertension and 
rheumatoid arthritis now face the increasing risk of a poor
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quality of life due to complications associated with such 
conditions.
To ensure both availability and affordability of medicines, 
policy makers should be reminded to prioritise drug 
procurement and supply. This calls for precision in 
estimating the required amounts so that enough medicines 
are procured in bulk from the cheapest suppliers.2 
Consequently there is saving of money and improvement 
in the management of drug supplies, leading to better 
service. For instance, local manufacturers could be 
persuaded to produce more accurate quantities of drugs if 
they knew the market size and required amounts more 
precisely.
. At the moment, statistics on chronic medical conditions 
are not readily available for use in forecasting drug 
requirements, though there are four major current methods 
of estimating drug needs.2 These are:
1. The consumption method, which uses records of past 
consumption'of individual drugs (adjusted for stock­
outs and projected changes in the drug utilisation) to 
project future need.
2. The morbidity method, which estimates the need for 
specific drugs based on the expected number of 
attendance, the incidence of common diseases, and 
standard treatm ent patterns for the diseases 
considered. ,
3. The adjusted consumption method, which uses data 
on disease incidence, drug consumption/utilisation, 
and/or drug expenditures from a “standard” supply 
system and extrapolates the consumption or utilisation 
rates to the target system, based on population 
coverage or service level to be provided.
4. • Service-level projection of budget requirements that
use the average drugprocurement cost per attendance 
or bed-day in different types of health facilities in the 
target system. However, all of these methods have 
the major drawback of relying on past consumption 
records that may not always be accurate or available.
This study was conducted specifically to develop a 
database for registering patients on chronic drug therapy, 
in order to monitor their drug consumption and find a more 
accurate (hence effective) method of quantifying drug 
requirements. Basically it was a “one off” exercise to 
establish a feasible database from which monitoring/ 
determination of patients’ drug consumption is possible at 
any given time. The same data collection form is used for 
the actual monitoring of any changes in drug consumption 
or the onset of any side effects, for a given number Of 
patients.
Materials and Methods 
Computer Programme.
The computer database was developed using computer 
software called Epi Info 6, which is distributed free of 
charge to public institutions by the Centre for Diseases 
Control and Prevention (CDC), USA and the World Health
Organisation (WHO).3 This is a word processing, database 
and statistics programme for analysing questionnaire data 
as well as organising study designs and results into text. 
Data Collection.
A data collection form was designed (see Appendix I), 
after which six field workers were recruited from the 
community and trained how to gather information. In the 
first phase they visited Chitungwiza’s four polyclinics (St 
Mary’s, Zengeza, Seke North and Seke South) and 
Chitungwiza General Hospital, to record details of patients 
from the patient registers at these institutions. They then 
visited the patients at their homes to obtain further 
information hitherto unavailable from the clinic/ hospital 
registers. Only those patients who were present at their 
homes and also consented to participate, were interviewed. 
This exercise covered the period 1 January 2000 to 30 
April 2001, with all the homes of chronic patients (then) 
attending Chitungwiza health centres being visited. Data 
were then entered into the Epi Info 6 computer database 
and analysed to assess its (database) effectiveness.
Appendix I: Data collection form.
CHRONIC THERAPY PATIENTS’ REGISTER
ID NUMBER.......................  ENTRY DATE..................  TODAY....................
PATIENT DETAILS
SURNAME..................................................................................... ..........................
FIRST NAME(S)............................... .......................................................................
DATE.OF BIRTH............... AGE...................................... S E X .............................
WEIGHT (KG)....................................  HEIGHT(cm)...........................................
RACE.................................................  NATIONAL ID NUMBER........................
MARITAL STATUS............................  OCCUPATION........................................
ADDRESS.........................................  C ITY........................................................
............................................................ COUNTRY...............................................
...........................................................  PHONE No..............................................
ROUTE OF ADMISSION
HOSPITAL.........................................  HOSPITAL No..........................................
CONSULTANT/GP PRINCIPAL............................................................................ :
HISTORY OF PRESENT ILLNESS 
DIAGNOSIS
ALLERGIES..............................................................
MANAGEMENT 
DRUG THERAPY
DRUG DAILY DOSE
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Sampling.
It should be noted that the study focused on developing 
and testing a research aid (database) for storing 
epidemiological information required for monitoring the 
drug consumption of a group of chronic patients. As such 
the “representativeness” of the “sample” lies in the coverage 
of all chronic conditions found at the health centres rather 
than in the statistical computation of “minimally acceptable” 
cases recorded per condition. The thrust was not to analyse 
distribution of characteristics within a “representative” 
sample and then extrapolate it to a wider population, but to 
find out whether it was feasible to install a database that 
could monitor actual drug consumption of a group of 
chronic patients. In short, the idea was to test whether the 
database could generate aggregated rather than individual 
data (see “Discussion” below) which could be of practical 
use, e.g. in drug purchasing.
The information gathered included biographical, 
residential address, weight, height, race, route of admission, 
diagnosis, allergies and drug therapy.
Results
The total number of patient files generated in the Epi Info 
6 database was 434. It was possible to retrieve readily the 
information on the amount of drugs being used by the 
patients with chronic medical conditions. The exact
quantities of the drugs were computed from the daily dose 
frequencies recorded in the database.
In addition to obtaining the amounts of drugs consumed, 
the database also generated epidemiological information 
such as the frequency of chronic conditions that affected 
the patients in Chitungwiza, as shown in Figure I.
According to this study, hypertension accounted for 
64% of the cases, followed by type II diabetes (14%), 
asthma (13%), epilepsy (5%) and type I diabetes (4%). 
However, since the sample had not been randomly selected 
this distribution is not statistically, valid and so does not 
reflect the situation at Chitungwiza health centres.
Figure II shows the drugs , that were being used by 
patients with hypertension and the number of patients 
taking each type of drug. The most frequently used was 
hydrochlorothiazide (37%), followed by methyldopa 
(28%), reserpine (9%), frusemide (5%) and potassium 
chloride (5%).
Figure III shows the medicines being used by diabetic 
patients, with the frequency of cases for each medicine 
clearly indicated.
Discussion
The use of modem computers in the health care sy stem has 
greatly improved the provision of health services.
A = asthma; Dl = type 1 diabetes; 02  =  type 11 diabetes; E =  epilepsy; CCF =  chronic cardiac failure; HTN = hypertension.
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Figure II: Number of hypertensive patients on each type of drug (n=321 cases).
ATL = atenolol; CAPT =  captopril; DIG = digoxin; HCT= hydrochlorothiazide; FRUS =  frusemide; MDP = methyl-dopa; NIF= nifedipine; PNL =  propranolol; PRZ 
-  prazosin; RES = reserpine; UZD = urazide.
Figure III: Number o f type 1 diabetes patients on each type o f insulin (n=22 cases).
actrapid isophane lente monotard protaphane
Type of Insulin
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Numerous studies on developing computer databases for 
health care delivery have been done in other countries, 
showing that these databases do improve the health care 
services quite significantly. For example, a study was 
carried out in Ravenna (Italy), to develop a computer- 
assisted system for improving the appropriateness and 
effectiveness of hypertension treatmeqt in clinical practice, 
and to install a database for both epidemiological and 
economical assessments,4 The findings confirmed the need 
for and feasibility of implementing the project in general 
practice.
In addition, research on the prevention of cardiovascular 
diseases in general practice also indicated that preventive 
detection and intervention programmes could be effective. 
Another study conducted in the Netherlands led to the 
development of a programme, the Nijmegen Hypertension 
Monitoring System (NHMS), which was a computer- 
assisted system of monthly feedback of treatment results 
and regular-m eetings of the participating general 
practitioners. The results showed the system’s effectiveness, 
feasibility and adaptability to other chronic diseases.5
At the University of Bristol another study was also done 
to assess the effect of computers and computer based 
clinical decision support systems (CDSS) on the 
management of hypertension. The results demonstrated an 
improvement in both patient administration and physician 
performance by using a computer.6
These studies demonstrated that the development of 
centralised health care databases was the key to creating 
more rational, systematic and cost-effective health care 
delivery systems.
The Epi Info 6 computer database developed in this 
study is an innovative method of continuously monitoring 
drug consumption. This is because it is consumption- 
based, specific for a disease condition and can be updated 
on a daily basis to record any changes in drug requirements. 
Consequently it is likely to produce much more accurate 
data for drug procurement agencies since it shows current 
consumption. At a secondary level the same database can 
also be used to monitor some patient specific responses to 
drugs, such as the adverse drug reactions in post marketing 
surveillance.
This data gathering method is not known to have been 
employed anywhere else before. One study was conducted 
in Gabon to develop a method of calculating the national 
drug requirements using the computer.7 The advantages of 
this method were found to be an improvement in the 
availability of essential drugs at all levels of the health 
system and a decrease of the required drug budget. However, 
the study was based on the consumption and morbidity 
methods. The consumption method does not normally 
address the appropriateness of past consumption patterns. 
If stock-outs have been widespread for long periods, it may 
be impossible to apply this method accurately.2 Morbidity- 
based quantification is the most complex and time- 
consuming. Morbidity data may not be available for all 
diseases and standard treatments may not really be used. 
Adjusted consumption is the method generally used if
neither the consumption-based nor the morbidity method 
is feasible. However, there is questionable comparability 
of patient populations, morbidity, and treatment practices. 
Service-level projection of budget requirements produces 
a rough estimate of financial needs for drug procurement. 
It does not estimate quantities of individual drugs. Also, 
there is variability in facility use, attendance, treatment 
patterns, and supply system efficiency.
The Epi Info database that was developed in this study is 
also useful in retrieving the information required to calculate 
the amount of drugs being used by patients on chronic 
therapy. Figures II and III illustrate how this information 
is presented in the database, with the actual quantity of 
each drug being extrapolated from these figures. The 
database also generates tables showing the daily doses of 
each drug being taken by each patient. For example, of the 
hypertensive patients on record, 213 were taking one 
hydrochlorothiazide 25mg tablet once daily, 16 were taking 
two tablets daily and five were taking one tablet twice 
daily. This amounted to 7 650 tablets, which are required 
every month by the hypertensive patients in Chitungwiza 
that were involved in this study.
This method of continuously monitoring the drug 
consumption of patients on chronic medication ensures a 
constant supply of drugs, which eases the standardisation 
of treatment practices through guaranteed availability of 
the requisite drugs. In addition, prescribes would tend to 
adhere to standard treatment guidelines since adequate 
resources would be available, thus eliminating the need to 
improvise with limited resources.
Limitations of Epi Info Database.
When retrieving data the Epi Info programme has some 
limitations in obtaining specific information with relative 
ease. For example, to know which drugs the patients are 
consuming, the command would be LIST DRUG and all 
the drugs would be listed. It is not possible to get the details 
of each individual drug separately.
However, the process of getting specific information 
from the Epi Info database only requires a few commands 
and a few easy, steps. The Epi Info database can be a very 
useful information source for epidemiology studies as 
demonstrated in Figure I. Such information is also useful 
for teaching and research purposes.
Conclusion
Storing details of patients on a centralised recording system 
potentially enhances better health care provision through 
patient-oriented education programmes and follow ups on 
a group of patients to monitor their progress (e.g. si gnificant 
drug effects) as well as to check for prescription changes. 
This project demonstrated that it is feasible for the Epi Info' 
6 computer programme to create a database for monitoring 
actual drug consumption by a group of patients on chronic 
drug therapy, as a way of accurately forecasting drug 
requirements.
The Epi Info 6 database developed in this study appears 
to be more precise and accurate than the current methods
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for quantifying drug requirements. One of its advantages is 
that field workers with low level training were able to 
collect patient data. In addition, computer data entry was 
basic enough to be taught to junior level workers, making 
it cost effective for use even in community settings. The 
computer database can also be a very useful information 
resource tool, hence it is recommended for implementation 
on a wider scale so that its advantages can be demonstrated 
clearly.
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Orbital exenterations and squamous ceil carcinoma of the 
conjunctiva at Sekuru Kaguvi Eye Unit, Zimbabwe
*R MASANGANISE, * *A MAGAVA
Abstract
Objectives: The aim of the audit was to determine the common orbital diseases necessitating orbital 
exenterations at Sekuru Kaguvi Hospital (SKH) between January and December 1999 and recommend ways 
of reducing the numbers of procedures done annually.
Design: Retrospective cross sectional study.
Setting: Department of Surgery, Parirenyatwa Hospital, University of Zimbabwe.
Subjects: 23 patients who underwent orbital exenterations at SKH over a one year period.
Main Outcome Measure: The nature of orbital tumours requiring orbital exenteration in Zimbabwe. 
Results: A total of 23 patients underwent orbital exenteration during the period under review. Of the 23 
patients, 13 (56.5%) had squamous cell carcinoma (SCCA) of the conjunctiva with orbital extensions, 69% 
of the 13 patients were females and the mean age of these patients was 37.2 years (interquartile range 28,48). 
Conclusions: People in tropical regions, where there is a high risk of squamous cell carcinoma of the 
conjunctiva in terms of increased predisposition to solar radiation, high prevalence of HIV and inadequate eye 
care services, should seek medical attention as soon as they notice a persistent conjunctival growth. 
Conjunctival tumours should be widely excised and material sent for histology to confirm diagnosis and 
clarity of excision margins. All patients diagnosed as having SCCA of the conjunctiva should be closely 
•"monitored to facilitate early detection of recurrences and institute appropriate treatment.
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